Immortalized Human Breast Cancer Associated Fibroblasts-SV40

Immortalized Human Breast Cancer-Associated Fibroblasts (BCAFs), established through the stable integration of the Simian Virus 40 (SV40) Large T antigen, constitute a sophisticated in vitro model for exploring the complex dynamics of the tumor microenvironment (TME). In breast cancer research, primary CAFs are critical mediators of tumor progression but are notoriously difficult to maintain due to early senescence and phenotypic drifting during ex vivo expansion. Our SV40-immortalized line overcomes these hurdles, providing a robust, high-fidelity platform for long-term mechanistic studies.

• Stable Activated Phenotype: These cells maintain the hallmark characteristics of activated myofibroblasts, including the persistent expression of Alpha-Smooth Muscle Actin (α-SMA) and Fibroblast Activation Protein (FAP). This ensures a consistent model for studying the stromal-driven metabolic reprogramming of cancer cells.
• Indefinite Proliferative Capacity: By bypassing the p53/pRb-mediated senescence checkpoints, this cell line offers an inexhaustible supply of standardized material. This scalability is essential for high-throughput screening (HTS) of novel compounds targeting the tumor stroma.
• Enhanced Secretome Fidelity: Our BCAFs reliably replicate the pro-tumorigenic secretome, including the release of specific growth factors (e.g., TGF-β, HGF) and pro-inflammatory cytokines (e.g., IL-6) that drive epithelial-mesenchymal transition (EMT) and chemoresistance in breast carcinoma cells.
• Optimized Co-culture Versatility: The line is engineered for high performance in 3D organoid models, transwell migration assays, and xenograft co-injection studies, providing a reproducible bridge between 2D cultures and complex in vivo stromal architecture.

Designed to replace the inherent variability of primary stromal cultures, the Immortalized Human BCAF-SV40 line provides a standardized, "assay-ready" system for pharmaceutical R&D. It is an indispensable tool for researchers aiming to decouple the intricate signaling pathways between the stroma and the tumor, ultimately accelerating the development of stroma-targeted therapies.